Dr. Babak Litkouhi is a board certified gynecologic oncologist who specializes in medical and surgical care for patients with gynecological cancers.
Dr. Litkouhi has extensive expertise with laparoscopic, robotic and open complex pelvic surgeries. As part of the Stamford Gynecologic Oncology Group, he offers the most comprehensive services in the area, including surgical care, access to novel clinical trials, and longitudinal care for patients with gynecologic cancers. He individualizes the care of his patients, and offers advanced treatments such as intraperitoneal chemotherapy, radical surgery, and sentinel lymph node staging using open and minimally invasive techniques.
Dr. Litkouhi works to improve the future of gynecologic cancer care through research and clinical trials. This gives his patients access to the latest treatments for a wide range of cancers. He has previously held faculty appointments at Harvard and New Jersey Medical Schools, and is currently faculty at Yale School of Medicine. He was won multiple teaching awards, and has co-authored numerous scientific and clinical publications in the field of gynecologic cancer.
Dr. Litkouhi strives to improve the quality of life for his patients, caring for both their physical and emotional needs. He provides long-term care to help patients adjust to how cancer and cancer care affects their lives throughout treatment and beyond.
Litkouhi, B. Sentinel lymph node mapping in endometrial cancer. Contemporary Oncology 2012, 4(2); 18-19.
Menderes G, Bonazzoli E, Bellone S, Black J, Altwerger G, Masserdotti A, Pettinella F, Zammataro L, Buza N, Hui P, Wong S, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD. SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression. Gynecol Oncol. 2017 Jul; 2017 May 1. PMID: 28473206.
Menderes G, Bonazzoli E, Bellone S, Black JD, Lopez S, Pettinella F, Masserdotti A, Zammataro L, Litkouhi B, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD. Efficacy of neratinib in the treatment of HER2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo. Med Oncol. 2017 May; 2017 Apr 10. PMID: 28397106.
Cocco E, Deng Y, Shapiro EM, Bortolomai I, Lopez S, Lin K, Bellone S, Cui J, Menderes G, Black JD, Schwab CL, Bonazzoli E, Yang F, Predolini F, Zammataro L, Altwerger G, de Haydu C, Clark M, Alvarenga J, Ratner E, Azodi M, Silasi DA, Schwartz PE, Litkouhi B, Saltzman WM, Santin AD. Dual-Targeting Nanoparticles for In Vivo Delivery of Suicide Genes to Chemotherapy-Resistant Ovarian Cancer Cells. Mol Cancer Ther. 2017 Feb; 2016 Dec 12. PMID: 27956521.
Bellone S, Bignotti E, Lonardi S, Ferrari F, Centritto F, Masserdotti A, Pettinella F, Black J, Menderes G, Altwerger G, Hui P, Lopez S, de Haydu C, Bonazzoli E, Predolini F, Zammataro L, Cocco E, Ferrari F, Ravaggi A, Romani C, Facchetti F, Sartori E, Odicino FE, Silasi DA, Litkouhi B, Ratner E, Azodi M, Schwartz PE, Santin AD. Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro. Gynecol Oncol. 2017 Jan; 2016 Nov 26. PMID: 27894751.
Black J, Menderes G, Bellone S, Schwab CL, Bonazzoli E, Ferrari F, Predolini F, De Haydu C, Cocco E, Buza N, Hui P, Wong S, Lopez S, Ratner E, Silasi DA, Azodi M, Litkouhi B, Schwartz PE, Goedings P, Beusker PH, van der Lee MM, Timmers CM, Dokter WH, Santin AD. SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression. Mol Cancer Ther. 2016 Aug; 2016 Jun 2. PMID: 27256376.
Cocco E, Lopez S, Black J, Bellone S, Bonazzoli E, Predolini F, Ferrari F, Schwab CL, Menderes G, Zammataro L, Buza N, Hui P, Wong S, Zhao S, Bai Y, Rimm DL, Ratner E, Litkouhi B, Silasi DA, Azodi M, Schwartz PE, Santin AD. Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo. Br J Cancer. 2016 Jul 26; 2016 Jun 28. PMID: 27351214.
Lester-Coll NH, Park HS, Rutter CE, Corso CD, Young MR, Ratner ES, Litkouhi B, Decker RH, Yu JB, Damast S. Who benefits from chemoradiation in stage III-IVA endometrial cancer? An analysis of the National Cancer Data Base. Gynecol Oncol. 2016 Jul; 2016 May 13. PMID: 27151429.
Ferrari F, Bellone S, Black J, Schwab CL, Lopez S, Cocco E, Bonazzoli E, Predolini F, Menderes G, Litkouhi B, Ratner E, Silasi DA, Azodi M, Schwartz PE, Santin AD. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro. J Exp Clin Cancer Res. 2015 Oct 17; 2015 Oct 17. PMID: 26474755.
Ahmad AK, Hui P, Litkouhi B, Azodi M, Rutherford T, McCarthy S, Xu ML, Schwartz PE, Ratner E. Institutional review of primary non-hodgkin lymphoma of the female genital tract: a 33-year experience. Int J Gynecol Cancer. 2014 Sep. PMID: 25010039.
Assistant Professor of Obstetrics, Gynecology, and Reproductive Sciences, Yale School of Medicine